通过调节PI3K/AKT通路,CHMP4C促进了膀癌的恶性进展
Xiao-Rui Chen1,2, Xue-Ying Tan2, Zong-Liang Zhang3
1Qingdao Medical College, Qingdao University, Qingdao, Shandong, China.
International journal of surgery (London, England)
|November 17, 2025
概括
高CHMP4C表达与膀癌预后和进展不佳相关. 抑制CHMP4C通过调节PI3K/Akt通路来阻碍瘤生长和侵袭,这表明CHMP4C是潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- CHMP4C (充电多胞体蛋白4C) 的表达与各种癌症有关.
- 它在膀癌进展中的特定作用和治疗潜力尚未完全阐明.
研究的目的:
- 为了研究CHMP4C在膀癌中的表达.
- 确定与瘤进展和患者预后的相关性.
- 探索CHMP4C作为潜在的治疗点.
主要方法:
- 对CHMP4C表达和生存预后的生物信息分析.
- 免疫组织化学测量瘤组织中的CHMP4C.
- 在膀癌细胞系中的CHMP4C的体外淘汰 (T24,5637).
- 对细胞增殖,细胞亡,迁移和入侵进行检测.
- 通过KEGG路径分析和西斑来评估PI3K/AKT信号.
主要成果:
- 与正常组织相比,CHMP4C在膀癌组织中显著上调.
- 高CHMP4C表达与增加的瘤等级和恶性相关.
- 通过CHMP4C的淘汰,抑制了扩散,迁移,入侵,并诱导了亡和G1阶段停止.
- CHMP4C调节PI3K/AKT通路;PI3K激动剂可以逆转淘汰效应.
结论:
- 增加CHMP4C表达与预后不佳,瘤等级更高以及膀癌中潜在的免疫治疗敏感性有关.
- 通过PI3K/Akt路径促进扩散,迁移,入侵和抑制亡,CHMP4C驱动膀癌的进展.
- 向CHMP4C是一个有前途的治疗策略,用于膀癌.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.6K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.7K
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
